Feng Li

US Patent:

7537765, May 26, 2009

Filed:

May 24, 2004

Appl. No.:

10/851637

Inventors:

Karl Salzwedel - Olney MD, US
Feng Li - Gaithersburg MD, US
Carl T. Wild - Gaithersburg MD, US
Graham P. Allaway - Darnestown MD, US
Eric O. Freed - Frederick MD, US

Assignee:

Panacos Pharmaceuticals, Inc. - Gaithersburg MD
The United States of America as represented by the Department of Health and Human Services - Washington DC

International Classification:

A61K 39/00
A61K 39/12
A61K 39/21
A61K 38/00

US Classification:

4241841, 530300, 4241861, 4241871, 4241881

Abstract:

Inhibition of HIV-1 replication by disrupting the processing of the viral Gag capsid (CA) protein (p24) from the CA-spacer peptide 1 (SP1) protein precursor (p25) is disclosed. Amino acid sequences containing a mutation in the Gag p25 protein, with the mutation resulting in a decrease in the inhibition of processing of p25 to p24 by dimethylsuccinyl betulinic acid or dimethylsuccinyl betulin, polynucleotides encoding such mutated sequences and antibodies that selectively bind such mutated sequences are also included. Methods of inhibiting, inhibitory compounds and methods of discovering inhibitory compounds that target proteolytic processing of the HIV Gag protein are included. In one embodiment, such compounds inhibit the interaction of the HIV protease enzyme with Gag by binding to Gag rather than to the protease enzyme. In another embodiment, viruses or recombinant proteins that contain mutations in the region of the Gag proteolytic cleavage site can be used in screening assays to identify compounds that target proteolytic processing.

US Patent:

8318425, Nov 27, 2012

Filed:

Jul 6, 2009

Appl. No.:

12/498157

Inventors:

Karl Salzwedel - Olney MD, US
Feng Li - Brookings SD, US
Carl T. Wild - Gaithersburg MD, US
Graham P. Allaway - Darnestown MD, US
Eric O. Freed - Frederick MD, US

Assignee:

The United States of America, as represented by the Secretary, Department & Human Services - Washington DC
Myrexis, Inc. - Salt Lake City UT

International Classification:

C12Q 1/70
C12Q 1/68
A01N 61/00
A01N 57/00
A61K 31/00
A61K 31/66

US Classification:

435 61, 435 5, 435 611, 435 612, 514 1, 514120, 514510

Abstract:

Inhibition of HIV-1 replication by disrupting the processing of the viral Gag capsid (CA) protein (p24) from the CA-spacer peptide 1 (SP1) protein precursor (p25) is disclosed. Amino acid sequences containing a mutation in the Gag p25 protein, with the mutation resulting in a decrease in the inhibition of processing of p25 to p24 by dimethylsuccinyl betulinic acid or dimethylsuccinyl betulin, polynucleotides encoding such mutated sequences and antibodies that selectively bind such mutated sequences are also included. Methods of inhibiting, inhibitory compounds and methods of discovering inhibitory compounds that target proteolytic processing of the HIV Gag protein are included. In one embodiment, such compounds inhibit the interaction of the HIV protease enzyme with Gag by binding to the Gag proteolytic cleavage site rather than to the protease enzyme. In another embodiment, viruses or recombinant proteins that contain mutations in the region of the Gag proteolytic cleavage site can be used in screening assays to identify compounds that target proteolytic processing.

US Patent:

20040265320, Dec 30, 2004

Filed:

Jan 29, 2004

Appl. No.:

10/766528

Inventors:

Karl Salzwedel - Olney MD, US
Feng Li - Gaithersburg MD, US
Carl Wild - Gaithersburg MD, US
Graham Allaway - Darnestown MD, US
Eric Freed - Frederick MD, US

International Classification:

A61K039/42

US Classification:

424/160100

Abstract:

Inhibition of HIV-1 replication by disrupting the processing of the viral Gag capsid (CA) protein (p24) from the CA-spacer peptide 1 (SP1) protein precursor (p25) is disclosed. Amino acid sequences containing a mutation in the Gag p25 protein, with the mutation resulting in a decrease in the inhibition of processing of p25 to p24 by dimethylsuccinyl betulinic acid or dimethylsuccinyl betulin, polynucleotides encoding such mutated sequences and antibodies that selectively bind such mutated sequences are also included. Methods of inhibiting, inhibitory compounds and methods of discovering inhibitory compounds that target proteolytic processing of the HIV Gag protein are included. In one embodiment, such compounds inhibit the interaction of the HIV protease enzyme with Gag by binding to the Gag proteolytic cleavage site rather than to the protease enzyme. In another embodiment, viruses or recombinant proteins that contain mutations in the region of the Gag proteolytic cleavage site can be used in screening assays to identify compounds that target proteolytic processing.

US Patent:

20080200550, Aug 21, 2008

Filed:

May 24, 2005

Appl. No.:

11/597431

Inventors:

Karl Salzwedel - Olney MD, US
Feng Li - Gaithersburg MD, US
Carl T. Wild - Gaithersburg MD, US
Graham P. Allaway - Darnestown MD, US
Eric O. Freed - Frederick MD, US

Assignee:

V.I. TECHNOLOGIES, INC. - Gaithersburg MD
THE GOV. OF US AS REP. BY THE SEC. DEP. OF HEALTH - Rockville MD

International Classification:

A61K 31/557

US Classification:

514573

Abstract:

Inhibition of HIV-1 replication by disrupting the processing of the viral Gag capsid (CA) protein (p24) from the CA-spacer peptide 1 (SP1) protein precursor (p25) is disclosed. Amino acid sequences containing a mutation in the Gag p25 protein, with the mutation resulting in a decrease in the inhibition of processing of p25 to p24 by dimethylsuccinyl betulinic acid or dimethylsuccinyl betulin, polynucleotides encoding such mutated sequences and antibodies that selectively bind such mutated sequences are also included. Methods of inhibiting, inhibitory compounds and methods of discovering inhibitory compounds that target proteolytic processing of the HIV Gag protein are included. In one embodiment, such compounds inhibit the interaction of the HIV protease enzyme with Gag by binding to Gag rather than to the protease enzyme. In another embodiment, viruses or recombinant proteins that contain mutations in the region of the Gag proteolytic cleavage site can be used in screening assays to identify compounds that target proteolytic processing.

US Patent:

20080233559, Sep 25, 2008

Filed:

Dec 21, 2007

Appl. No.:

11/962315

Inventors:

Karl SALZWEDEL - Olney MD, US
Feng Li - Gaithersburg MD, US
Carl T. Wild - Gaithersburg MD, US
Graham P. Allaway - Darnestown MD, US
Eric O. Freed - Frederick MD, US

International Classification:

C12Q 1/70

US Classification:

435 5

Abstract:

Inhibition of HIV-1 replication by disrupting the processing of the viral Gag capsid (CA) protein (p24) from the CA-spacer peptide 1 (SP1) protein precursor (p25) is disclosed. Amino acid sequences containing a mutation in the Gag p25 protein, with the mutation resulting in a decrease in the inhibition of processing of p25 to p24 by dimethylsuccinyl betulinic acid or dimethylsuccinyl betulin, polynucleotides encoding such mutated sequences and antibodies that selectively bind such mutated sequences are also included. Methods of inhibiting, inhibitory compounds and methods of discovering inhibitory compounds that target proteolytic processing of the HIV Gag protein are included. In one embodiment, such compounds inhibit the interaction of the HIV protease enzyme with Gag by binding to Gag rather than to the protease enzyme. In another embodiment, viruses or recombinant proteins that contain mutations in the region of the Gag proteolytic cleavage site can be used in screening assays to identify compounds that target proteolytic processing.

US Patent:

20110294806, Dec 1, 2011

Filed:

Dec 11, 2009

Appl. No.:

12/998873

Inventors:

Jiwei Qi - West Roxbury MA, US
Yihan Wang - Newton MA, US
Feng Li - Winchester MA, US
William C. Shakespeare - Southborough MA, US
Anna Kohlmann - Winchster MA, US
David C. Dalgarno - Brookline MA, US
Xiaotian Zhu - Newton MA, US

Assignee:

ARIAD Pharmaceuticals, Inc. - Cambridge MA

International Classification:

A61K 31/437
A61P 35/00
A61K 31/506
C07D 471/04
A61K 31/5377

US Classification:

5142345, 546113, 544127, 544333, 514300, 514256

Abstract:

This invention relates to compounds of the general formula (I) in which the variable groups are as defined herein, and to their preparation and use.

US Patent:

20120202776, Aug 9, 2012

Filed:

May 21, 2009

Appl. No.:

12/736910

Inventors:

Yihan Wang - Newton MA, US
Wei-Sheng Huang - Acton MA, US
Shuangying Liu - Wellesley MA, US
William C. Shakespeare - Southborough MA, US
R. Mathew Thomas - Sharon MA, US
Jiwei Qi - West Roxbury MA, US
Feng Li - Winchester MA, US
Xiaotian Zhu - Newton MA, US
Anna Kohlmann - Winchester MA, US
David C. Dalgarno - Brookline MA, US
Jan Antoinette C. Romero - Somerville MA, US
Dong Zou - Concord MA, US

Assignee:

ARIAD Pharmaceuticals, Inc. - Cambridge MA

International Classification:

A61K 31/675
C07F 9/6512
C07F 9/6561
A61P 35/00
C07F 9/6509
C07F 9/6521
C07F 9/58
C07F 9/6558
C07F 9/6584

US Classification:

514 81, 544243, 544122, 544244, 544232, 544195, 544113, 514 86, 514 80, 514 85, 546 22, 514 89, 514 84, 514 90

Abstract:

The invention features compounds of the general formula (I) in which the variable groups are as defined herein, and to their preparation and use.

US Patent:

20120315338, Dec 13, 2012

Filed:

Dec 3, 2010

Appl. No.:

13/512827

Inventors:

Feng Li - Marlborough MA, US

Assignee:

Stem Cell & Regenerative Medicine International, Inc. - Marlborough MA

International Classification:

C12N 5/078
A61K 35/14
A61P 7/04
G01N 33/566

US Classification:

424532, 435377, 435372, 435325, 435373, 435354, 435 721

Abstract:

The present invention provides a method of generating megakaryocytes and platelets. In various embodiments, method involves the use of human embryonic stem cell derived hemangioblasts for differentiation into megakaryocytes and platelets under serum and stromal-free condition. In this system, hESCs are directed towards megakaryocytes through embryoid body formation and hemangioblast differentiation. Further provided is a method of treating a subject in need of platelet transfusion.